X

Clinical Trials

Contact Us

A031901

Study Number: A031901
Please Note:

This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors. Immunotherapy with monoclonal antibodies, such as avelumab, durvalumab, pembrolizumab, atezolizumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stopping immune checkpoint inhibitors early may still make the tumor shrink and patients may have similar survival rates as the patients who continue treatment. Stopping treatment early may also lead to fewer treatment-related side effects, an improvement in mental health, and a lower cost burden to patients.

Available Sites
  • Missouri Baptist Medical Center
  • Missouri Baptist Outpatient Center – Sunset Hills
  • Missouri Baptist Sullivan Hospital
  • Sainte Genevieve County Memorial Hospital
  • Parkland Health Center - Farmington
Contact Person(s)
  • MBMC, Brandi Koziatek, 314-996-5898

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.